LiquidiaLQDA -1.39%67 Days Inventory is 201.36 as of Mar. 2026, which is 16% above its 10-year median of 173.16. GuruFocus rates LQDA with a GF Score™ of 67/100 and a GF Value™ of $223.17 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 917 Drug Manufacturers companies, Liquidia ranks worse than 77.75% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Liquidia's Average Total Inventories for the
three
months ended in Mar. 2026 was $26.2 Mil. Liquidia's Cost of Goods Sold for the
three
months ended in Mar. 2026 was $11.9 Mil.
Hence, Liquidia's Days Inventory for the
three
months ended in Mar. 2026 was 201.36.
The historical rank and industry rank for Liquidia's Days Inventory or its related term are showing as below:
LQDA'
s Days Inventory Range Over the Past 10 Years
Min: 14.96 Med: 173.16 Max: 331.36
Current: 262.05
During the past 10 years, Liquidia's highest Days Inventory was 331.36. The lowest was 14.96. And the median was 173.16.
LQDA's Days Inventory is ranked worse than 77.75% of 917
companies
in the Drug Manufacturers industry
Industry Median: 164.48
vs LQDA: 262.05
Liquidia's Days Inventory
increased
from Mar. 2025 (47.82) to Mar. 2026 (201.36).
It might indicate that Liquidia's sales slowed down.
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Liquidia's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.45.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Liquidia's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.20.
Liquidia (NAS:LQDA) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Liquidia's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Liquidia's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Liquidia Days Inventory Related Terms
Liquidia Days Inventory Historical Data
* Premium members only.
The historical data trend for Liquidia's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LQDA vs LNTH, HIMS, AMRX: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Liquidia's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Liquidia Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Liquidia's Days Inventory distribution charts can be found below:
* The bar in red indicates where Liquidia's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Liquidia (LQDA) has a Days Inventory of 201.36 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Liquidia and its competitors. This is 16% above median its historical median of 173.16. Over the past decade, Liquidia's Days Inventory has ranged from 14.96 to 331.36. According to the industry distribution chart, Liquidia ranks #713 out of 917 companies in the Drug Manufacturers industry, placing it in the top 77.8%.
Is Liquidia's Days Inventory too high?
Liquidia's current Days Inventory of 201.36 is 16% above median its 10-year median of 173.16. Over the past 10 years, this metric has ranged from a low of 14.96 to a high of 331.36. The Drug Manufacturers industry median Days Inventory is 164.48. Liquidia's value of 201.36 is 22.4% above this industry median. Based on the distribution chart, Liquidia ranks #713 out of 917 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Liquidia has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Liquidia's Days Inventory compare to LNTH and HIMS?
According to the Drug Manufacturers industry distribution chart, Liquidia ranks #713 out of 917 companies for Days Inventory. This places Liquidia in the lower half of its industry. The industry median Days Inventory is 164.48. Liquidia's value of 201.36 is 22.4% above this benchmark. Historically, Liquidia's own Days Inventory has ranged from 14.96 to 331.36 over the past decade. While the company's 10-year median is 173.16 vs. the industry median of 164.48, Liquidia has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.48, based on 917 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Liquidia's current Days Inventory of 201.36 is 22.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Liquidia and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Liquidia's current Days Inventory is 201.36, which is 16% above median its own 10-year median of 173.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Liquidia stock overvalued right now?
Based on GuruFocus' analysis, Liquidia (LQDA) is currently considered Possible Value Trap. The stock's GF Value™ is $223.17, compared to a current price of $78.62 — trading 64.8% below its estimated fair value. The current Days Inventory is 201.36, which is 16% above median its 10-year median of 173.16 and 22.4% above the Drug Manufacturers industry median of 164.48. Liquidia's overall GF Score™ is 67/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Liquidia (LQDA), the current Days Inventory is 201.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Liquidia (LQDA) Overvalued in 2026?
Based on GuruFocus' analysis, Liquidia stock appears to be undervalued.
The current stock price of $78.62 is trading 64.8% below its estimated GF Value™ of $223.17.
GuruFocus considers Liquidia to be Possible Value Trap.
Key valuation signals for LQDA:
Days Inventory: 201.36 (16% above median its 10-year median of 173.16)
GF Value™: $223.17 vs. price of $78.62 (64.8% below fair value)
Industry Position: 22.4% above the Drug Manufacturers median (#713 of 917)
No single metric tells the full story. See the LQDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
67GF Score
Get the complete analysis for LQDA
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LQDA has been successfully added to your 
